My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Gilead Sciences (NQ:GILD)

126.52 -0.66 (-0.52%)

Streaming Delayed Price Updated: 2:54 PM EST, Nov 19, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Gilead Sciences

< Previous 1 2

...

27 28 29 30 31 32 33 34 35

...

68 69 Next >

Gilead Squashes Expectations On The Back Of A Bullish Move For Its Cancer Drugs ↗

November 07, 2023

The biotech company makes three notable treatments for cancer.

Via Investor's Business Daily

Positive News For Gastric Cancers - Gilead/Arcus Biosciences' Combination Cancer Therapy Shows Encouraging Clinical Activity ↗

November 07, 2023

Gilead Sciences Inc (NASDAQ: GILD) and Arcus Biosciences Inc (NYSE: RCUS) announced that domvanalimab plus zimberelimab and chemotherapy showed encouraging overall response rate (ORR) and six-month...

Via Benzinga

S&P 500, Nasdaq Set To Break 6-Day Rally Today? Traders Await Fed Cues, Analyst Says Seasonal Rally Has Started With Gusto ↗

November 07, 2023

Sentiment appears to have dipped after a six-session winning streak. Stock futures indicate a modestly lower opening on Tuesday as small and mid-cap earnings reports gain momentum.

Via Benzinga

Topics Economy Stocks

If You Invested $100 In This Stock 20 Years Ago, You Would Have $1,200 Today ↗

November 06, 2023

Via Benzinga

This Is What Whales Are Betting On Gilead Sciences ↗

November 02, 2023

Via Benzinga

Comparative Study: Gilead Sciences And Industry Competitors In Biotechnology Industry ↗

October 20, 2023

Via Benzinga

Here's How Much $100 Invested In Gilead Sciences 20 Years Ago Would Be Worth Today ↗

October 13, 2023

Via Benzinga

Gilead and Arcus Announce New Data Showing Encouraging Clinical Activity of Anti-TIGIT Domvanalimab-Containing Regimen as First-line Treatment for Upper GI Cancers

November 06, 2023

From Gilead Sciences, Inc.

Via Business Wire

Fed Holds Rates Steady, Powell's Cautious Stance Soothes Investors, Labor Market Softens: The Week In The Markets ↗

November 03, 2023

Markets bounced back decisively this week, shrugging off prior volatile months marked by heightened geopolitical tensions. The resurgence of risk sentiment ignited a relief rally in both equities and...

Via Benzinga

Topics Bonds Economy

Gilead to Present Late Breaking Data and Real World Evidence Highlighting Key Hepatitis Indications at The Liver Meeting® 2023

November 03, 2023

From Gilead Sciences, Inc.

Via Business Wire

Gilead and Kite Oncology Present Data Demonstrating Car T-cell Therapy Survival Benefit and Showcasing Latest Advances in Blood Cancer Portfolio at ASH 2023

November 02, 2023

From Gilead Sciences, Inc.

Via Business Wire

Leidos Sees Robust Demand In Digital Modernization, Raises Annual Outlook ↗

October 31, 2023

Leidos Holdings, Inc (NYSE: LDOS) reported third-quarter FY23 revenue growth of 9% year-over-year to $3.92 billion, beating the consensus of $3.77 billion.

Via Benzinga

Kite and Epic Bio Announce Collaboration to Develop New Therapies for Cancer

October 31, 2023

From Gilead Sciences, Inc.

Via Business Wire

3 Pharma Stocks That Are Screaming Buys in October ↗

October 26, 2023

Each company delivers an above-average dividend and revenue growth.

Via The Motley Fool

10 Health Care Stocks With Whale Alerts In Today's Session ↗

October 24, 2023

Via Benzinga

Gilead Named Number One Overall Philanthropic Funder of HIV-Related Programs for Second Year in a Row by Funders Concerned About AIDS

October 24, 2023

From Gilead Sciences, Inc.

Via Business Wire

7 Healthcare Stocks to invest in for a Healthy Future ↗

October 20, 2023

Considering today's economic uncertainty and market turns, healthcare stocks may be one of the few winning sectors. Here are the winners.

Via InvestorPlace

New Data Presented at EACS 2023 Further Demonstrate Strong Clinical Profile of Twice-Yearly Sunlenca® for Adults With Multi-Drug Resistant HIV

October 20, 2023

From Gilead Sciences, Inc.

Via Business Wire

Pfizer Decides To Raise COVID-19 Treatment Pill Price, Defends Itself Amid Criticism for Cost Increase ↗

October 19, 2023

Pfizer Inc (NYSE: PFE) is reportedly gearing up to price its Covid-19 drug Paxlovid at $1,390 for a five-day course, more than double what the U.S. government initially paid for it, at $529.

Via Benzinga

Vertex Pharmaceuticals, Gilead Sciences And 2 Other Stocks Insiders Are Selling ↗

October 19, 2023

The Nasdaq 100 closed lower by over 200 points on Wednesday. Investors, meanwhile, focused on some notable insider trades.

Via Benzinga

Real-World Evidence Reinforces Biktarvy® as a Long-Term Treatment Option With a High Barrier to Resistance for People With HIV and a Range of Comorbidities

October 19, 2023

From Gilead Sciences, Inc.

Via Business Wire

Why AstraZeneca's Disappointing Lung Cancer Update Also Tripped Gilead Stock ↗

October 18, 2023

The companies are hoping to use antibody drug conjugates in lung cancer patients.

Via Investor's Business Daily

Gilead Sciences Announces New Clinical Trial in Europe to Assess Lenacapavir for HIV Prevention as Part of Landmark Purpose Program

October 18, 2023

From Gilead Sciences, Inc.

Via Business Wire

Why Is Assembly Biosciences (ASMB) Stock Up 92% Today? ↗

October 17, 2023

Assembly Biosciences stock is taking off with heavy trading of ASMB shares after the company announced a new collaboration agreement!

Via InvestorPlace

Hepatitis-Focused Assembly Biosciences Stock Trading Over 100% Higher: Here's Why ↗

October 17, 2023

Gilead Sciences Inc (NASDAQ: GILD) and Assembly Biosciences Inc (NASDAQ: ASMB) have entered into a 12-year partnership.

Via Benzinga

Gilead and Assembly Biosciences Establish Partnership to Develop Next-Generation Therapeutics for Serious Viral Diseases

October 17, 2023

From Gilead Sciences, Inc.

Via Business Wire

Gilead and Kite Oncology Present Important New Data Across Multiple Difficult-to-Treat Cancers at ESMO Congress 2023

October 16, 2023

From Gilead Sciences, Inc.

Via Business Wire

Gilead Demonstrates the Impact of Global Collaboration in Advancing HIV Research and Health Equity at EACS 2023

October 16, 2023

From Gilead Sciences, Inc.

Via Business Wire

2 Dirt Cheap High-Yield Dividend Stocks to Buy Right Now ↗

October 15, 2023

These companies aren't getting the respect they deserve.

Via The Motley Fool

Gilead Sciences to Release Third Quarter 2023 Financial Results on Tuesday, November 7, 2023

October 12, 2023

From Gilead Sciences, Inc.

Via Business Wire

< Previous 1 2

...

27 28 29 30 31 32 33 34 35

...

68 69 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.